Evidence map›Paper›PMID 29447163›Full record

ArticlePLoS genetics2018

Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study.

Kevin H Eng, J Brian Szender, John Lewis Etter, Jasmine Kaur, Samantha Poblete, Ruea-Yea Huang, Qianqian Zhu, Katherine A Grzesik, Sebastiano Battaglia, Rikki Cannioto and 6 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Kevin H EngDepartments of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo NY, United States of America.
J Brian SzenderGynecologic Oncology, Roswell Park Cancer Institute, Buffalo NY, United States of America.
John Lewis EtterCancer Prevention and Control, Roswell Park Cancer Institute, Buffalo NY, United States of America.
Jasmine KaurGynecologic Oncology, Roswell Park Cancer Institute, Buffalo NY, United States of America.
Samantha PobleteGynecologic Oncology, Roswell Park Cancer Institute, Buffalo NY, United States of America.
Ruea-Yea HuangCancer Genetics and Genomics, Roswell Park Cancer Institute, Buffalo NY, United States of America.
Qianqian ZhuDepartments of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo NY, United States of America.
Katherine A GrzesikDepartments of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo NY, United States of America.ORCID 0000-0002-9176-4684
Sebastiano BattagliaCancer Genetics and Genomics, Roswell Park Cancer Institute, Buffalo NY, United States of America.
Rikki CanniotoCancer Prevention and Control, Roswell Park Cancer Institute, Buffalo NY, United States of America.
John J KrolewskiCancer Genetics and Genomics, Roswell Park Cancer Institute, Buffalo NY, United States of America.
Emese ZsirosGynecologic Oncology, Roswell Park Cancer Institute, Buffalo NY, United States of America.
Peter J FrederickGynecologic Oncology, Roswell Park Cancer Institute, Buffalo NY, United States of America.
Shashikant B LeleGynecologic Oncology, Roswell Park Cancer Institute, Buffalo NY, United States of America.
Kirsten B MoysichCancer Prevention and Control, Roswell Park Cancer Institute, Buffalo NY, United States of America.
Kunle O OdunsiGynecologic Oncology, Roswell Park Cancer Institute, Buffalo NY, United States of America.
Roswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
RPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2013 to 2025
$19.6M
Novel immunological biomarkers ovarian cancer prognosisR01CA188900 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B., SEGAL, BRAHM H. · 2015 to 2019
$3.3M
Postdoctoral Research Training in Surgical OncologyT32CA108456 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI YENDAMURI, SAIKRISHNA · 2006 to 2020
$2.8M
Informatic Methods for Differential Signaling and Immune Co-Regulatory ExpressionK01LM012100 · NLM · ROSWELL PARK CANCER INSTITUTE CORP · PI ENG, KEVIN HASEGAWA · 2015 to 2017
$502k
NCI NIH HHS P30 CA016056NCI NIH HHS P50 CA159981NCI NIH HHS R01 CA188900NCI NIH HHS T32 CA108456NIH HHS K01LM012100NIH HHS P50CA159981NLM NIH HHS K01 LM012100
6 · The paper itself

Abstract

Given prior evidence that an affected woman conveys a higher risk of ovarian cancer to her sister than to her mother, we hypothesized that there exists an X-linked variant evidenced by transmission to a woman from her paternal grandmother via her father. We ascertained 3,499 grandmother/granddaughter pairs from the Familial Ovarian Cancer Registry at the Roswell Park Cancer Institute observing 892 informative pairs with 157 affected granddaughters. We performed germline X-chromosome exome sequencing on 186 women with ovarian cancer from the registry. The rate of cancers was 28.4% in paternal grandmother/granddaughter pairs and 13.9% in maternal pairs consistent with an X-linked dominant model (Chi-square test X2 = 0.02, p = 0.89) and inconsistent with an autosomal dominant model (X2 = 20.4, p<0.001). Paternal grandmother cases had an earlier age-of-onset versus maternal cases (hazard ratio HR = 1.59, 95%CI: 1.12-2.25) independent of BRCA1/2 status. Reinforcing the X-linked hypothesis, we observed an association between prostate cancer in men and ovarian cancer in his mother and daughters (odds ratio, OR = 2.34, p = 0.034). Unaffected mothers with affected daughters produced significantly more daughters than sons (ratio = 1.96, p<0.005). We performed exome sequencing in reported BRCA negative cases from the registry. Considering age-of-onset, one missense variant (rs176026 in MAGEC3) reached chromosome-wide significance (Hazard ratio HR = 2.85, 95%CI: 1.75-4.65) advancing the age of onset by 6.7 years. In addition to the well-known contribution of BRCA, we demonstrate that a genetic locus on the X-chromosome contributes to ovarian cancer risk. An X-linked pattern of inheritance has implications for genetic risk stratification. Women with an affected paternal grandmother and sisters of affected women are at increased risk for ovarian cancer. Further work is required to validate this variant and to characterize carrier families.

Indexed as

Genes, X-LinkedHeredityAdultAge of OnsetBreast NeoplasmsFamilyFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedModels, GeneticOvarian NeoplasmsPaternal InheritancePedigreeRegistries

Identifiers

PMID29447163
PMCPMC5813894
OpenAlexW2785381890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.